Metreleptin (recombinant methionyl human leptin), an analog of human leptin, has also been studied as a potential treatment for obesity and diabetes. About Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN®(pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com. This press release contains forward-looking statements about Amylin, which involve risks and uncertainties.